-
1
-
-
84866597106
-
Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up
-
Cardoso F, Harbeck N, Fallowfield S, Kyriakides S, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2012;23(suppl 7):vii11-vii19.
-
(2012)
Ann Oncol.
, vol.23
, pp. vii11-vii19
-
-
Cardoso, F.1
Harbeck, N.2
Fallowfield, S.3
Kyriakides, S.4
Senkus, E.5
-
2
-
-
46949103546
-
Metastatic breast cancer: The treatment challenge
-
Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008;8:224-233.
-
(2008)
Clin Breast Cancer.
, vol.8
, pp. 224-233
-
-
Jones, S.E.1
-
3
-
-
84868598489
-
Taxanes for the treatment of metastatic breast cancer
-
Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer. 2012;6:159-171.
-
(2012)
Breast Cancer.
, vol.6
, pp. 159-171
-
-
Gradishar, W.J.1
-
5
-
-
32944482677
-
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
-
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 7794-7803
-
-
Gradishar, W.J.1
Tjulandin, S.2
Davidson, N.3
-
6
-
-
2942655407
-
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342
-
Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol. 2004;22:2061-2068.
-
(2004)
J Clin Oncol.
, vol.22
, pp. 2061-2068
-
-
Winer, E.P.1
Berry, D.A.2
Woolf, S.3
-
7
-
-
84880182345
-
nab-Paclitaxel mechanisms of action and delivery
-
Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170:365-372.
-
(2013)
J Control Release.
, vol.170
, pp. 365-372
-
-
Yardley, D.A.1
-
8
-
-
68949114599
-
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer
-
Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611-3619.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 3611-3619
-
-
Gradishar, W.J.1
Krasnojon, D.2
Cheporov, S.3
-
9
-
-
84867058051
-
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival
-
Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012;12:313-321.
-
(2012)
Clin Breast Cancer.
, vol.12
, pp. 313-321
-
-
Gradishar, W.J.1
Krasnojon, D.2
Cheporov, S.3
-
10
-
-
38049079353
-
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
-
Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7:850-856.
-
(2007)
Clin Breast Cancer.
, vol.7
, pp. 850-856
-
-
Blum, J.L.1
Savin, M.A.2
Edelman, G.3
-
11
-
-
24944505659
-
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
-
Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23:6019-6026.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 6019-6026
-
-
Ibrahim, N.K.1
Samuels, B.2
Page, R.3
-
12
-
-
77956184020
-
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
-
Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123(2):427-435.
-
(2010)
Breast Cancer Res Treat.
, vol.123
, Issue.2
, pp. 427-435
-
-
Lobo, C.1
Lopes, G.2
Baez, O.3
-
13
-
-
84889100961
-
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer
-
Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013;13(6):416-420.
-
(2013)
Clin Breast Cancer.
, vol.13
, Issue.6
, pp. 416-420
-
-
Hamilton, E.1
Kimmick, G.2
Hopkins, J.3
-
14
-
-
0034594628
-
New guidelines to evaluate the response to treatment on solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment on solid tumors. J Natl Cancer Inst. 2000;92(3):205-216.
-
(2000)
J Natl Cancer Inst.
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
15
-
-
84929163847
-
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: Prospective evaluation of activity, safety, and quality of life
-
Palumbo R, Sottotetti F, Trifirò G, et al. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther. 2015;9:1-11.
-
(2015)
Drug Des Devel Ther.
, vol.9
, pp. 1-11
-
-
Palumbo, R.1
Sottotetti, F.2
Trifirò, G.3
-
16
-
-
84876173108
-
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: The COSTANza study
-
Lazzaro C, Bordonaro R, Cognetti F, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res. 2013;5:125-135.
-
(2013)
Clinicoecon Outcomes Res.
, vol.5
, pp. 125-135
-
-
Lazzaro, C.1
Bordonaro, R.2
Cognetti, F.3
|